Federal Circuit Affirms Invalidity of AliveCor Heart Monitoring Patents Against Apple
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | AliveCor, Inc. v. Apple, Inc. |
| Case Number | 23-1512 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from PTAB |
| Duration | Feb 2023 – Mar 2025 25 months |
| Outcome | Defendant Win – Patent Unpatentable / Cancelled |
| Patents at Issue | |
| Accused Products | Apple Watch Series 4+ (ECG functionality) |
Case Overview
The Parties
⚖️ Plaintiff
Medical technology company specializing in AI-driven electrocardiogram (ECG) hardware and software solutions, including FDA-cleared personal cardiac monitoring devices.
🛡️ Defendant
Global technology leader, integrated cardiac health monitoring into Apple Watch, placing it in direct competitive and intellectual property conflict with specialized medtech innovators.
The Patent at Issue
This case involved **U.S. Patent No. US10595731B2**, covering methods and systems for arrhythmia tracking and scoring. The patent covered algorithmic methods for detecting, tracking, and scoring cardiac arrhythmias — including atrial fibrillation — through wearable monitoring devices.
- • US10595731B2 — Methods and systems for arrhythmia tracking and scoring
Litigation Timeline & Procedural History
The appellate proceeding was filed on **February 15, 2023**, before the Court of Appeals for the Federal Circuit in the District of Columbia, and concluded **March 7, 2025** — a duration of **751 days** (approximately 25 months).
The appeal arose from an underlying **patentability/invalidity action**, consistent with PTAB inter partes review (IPR) proceedings, where Apple challenged the validity of AliveCor’s patent claims. The USPTO’s PTAB had rendered an unpatentability determination — finding the claims of US10595731B2 invalid — which AliveCor subsequently appealed to the Federal Circuit.
📎 Case documents available via PACER (Case No. 23-1512). Patent details accessible through the USPTO Patent Full-Text Database.
Developing cardiac monitoring tech?
Check if your health monitoring innovation might infringe this or related patents.
The Verdict & Legal Analysis
Outcome
The Federal Circuit issued an unambiguous disposition: **AFFIRMED**. The court upheld PTAB’s finding that the claims of US10595731B2 are **unpatentable**, resulting in their cancellation. No damages award is associated with this proceeding, as the action centered on patent validity rather than infringement liability. The affirmance extinguishes AliveCor’s enforceable rights under this specific patent, removing it as an assertion vehicle against Apple or any third party.
Verdict Cause Analysis & Legal Significance
The basis of termination is recorded as **Unpatentable**, arising from an **Invalidity/Cancellation Action** under the patentability verdict cause. While the Federal Circuit’s specific written opinion details were not disclosed in the underlying case data, the procedural posture establishes that the invalidity challenge succeeded at PTAB and survived appellate review.
This decision reinforces several critical doctrinal and procedural realities for digital health patent litigation:
- **PTAB Remains a Powerful Invalidity Forum:** Apple’s strategy of challenging AliveCor’s patents via PTAB rather than purely through district court affirmative defenses proved effective.
- **Algorithmic Health Claims Face Elevated Scrutiny:** Patents covering software-implemented methods for physiological monitoring — particularly when broad enough to encompass consumer wearable applications — continue to face significant prior art and § 101 eligibility challenges.
- **Federal Circuit Deference to PTAB Findings:** The affirmance without modification signals the PTAB record was well-constructed, highlighting the importance of building a thorough IPR record at the trial level.
Drafting health tech patents?
Learn from this case. Use AI to draft stronger claims that can withstand PTAB challenges.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in algorithmic health monitoring. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation for your IP portfolio.
- Monitor AliveCor’s continuation patent activity post-cancellation
- See how PTAB challenges impact digital health portfolios
- Understand claim differentiation strategies for health tech
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Algorithm-based cardiac monitoring
1 Patent Cancelled
US10595731B2 deemed unpatentable
PTAB Strategy Validated
Effective for invalidating software patents
✅ Key Takeaways
For Patent Attorneys & Litigators
Federal Circuit affirmed PTAB cancellation of US10595731B2 — PTAB invalidity strategy succeeded for Apple.
Search related case law →Algorithmic arrhythmia detection claims remain vulnerable to prior art challenges; claim drafting precision is critical.
Explore precedents →For IP Professionals & R&D Teams
FTO clearance in cardiac monitoring technology must account for continuation families, not just issued patents.
Start FTO analysis for my product →PTAB cancellations create design freedom windows – but require ongoing monitoring for related claim activity.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.